Citadel Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-239
| Closed | -$545 | – | 15550 |
|
|
2024
Q2 | $545 | Buy |
239
+227
| +1,892% | +$867 | ﹤0.01% | 13966 |
|
|
2024
Q1 | $52 | Sell |
12
-43,954
| -100% | -$153K | ﹤0.01% | 14442 |
|
|
2023
Q4 | $134K | Sell |
43,966
-96,852
| -69% | -$182K | ﹤0.01% | 10567 |
|
|
2023
Q3 | $203K | Sell |
140,818
-1,090
| -0.8% | -$2.11K | ﹤0.01% | 9888 |
|
|
2023
Q2 | $353K | Buy |
141,908
+40,145
| +39% | +$110K | ﹤0.01% | 8681 |
|
|
2023
Q1 | $273K | Sell |
101,763
-193,160
| -65% | -$928K | ﹤0.01% | 9564 |
|
|
2022
Q4 | $1.6M | Buy |
294,923
+193,835
| +192% | +$1.62M | ﹤0.01% | 5897 |
|
|
2022
Q3 | $1.26M | Sell |
101,088
-230,806
| -70% | -$2.64M | ﹤0.01% | 6491 |
|
|
2022
Q2 | $1.64M | Buy |
331,894
+38,858
| +13% | +$215K | ﹤0.01% | 5963 |
|
|
2022
Q1 | $2.23M | Buy |
293,036
+25,631
| +10% | +$243K | ﹤0.01% | 5854 |
|
|
2021
Q4 | $2.73M | Buy |
267,405
+247,871
| +1,269% | +$3.16M | ﹤0.01% | 5525 |
|
|
2021
Q3 | $262K | Sell |
19,534
-22,588
| -54% | -$368K | ﹤0.01% | 11369 |
|
|
2021
Q2 | $924K | Sell |
42,122
-34,254
| -45% | -$761K | ﹤0.01% | 8573 |
|
|
2021
Q1 | $1.84M | Sell |
76,376
-102,004
| -57% | -$2.37M | ﹤0.01% | 6598 |
|
|
2020
Q4 | $3.21M | Sell |
178,380
-82,384
| -32% | -$1.23M | ﹤0.01% | 4482 |
|
|
2020
Q3 | $3.01M | Buy |
260,764
+180,673
| +226% | +$2.98M | ﹤0.01% | 3981 |
|
|
2020
Q2 | $1.94M | Sell |
80,091
-45,178
| -36% | -$747K | ﹤0.01% | 4632 |
|
|
2020
Q1 | $1.38M | Sell |
125,269
-4,107
| -3% | -$76.7K | ﹤0.01% | 4767 |
|
|
2019
Q4 | $3.42M | Buy |
129,376
+111,852
| +638% | +$2.62M | ﹤0.01% | 3606 |
|
|
2019
Q3 | $400K | Sell |
17,524
-5,572
| -24% | -$176K | ﹤0.01% | 7134 |
|
|
2019
Q2 | $708K | Sell |
23,096
-255,412
| -92% | -$5.38M | ﹤0.01% | 6259 |
|
|
2019
Q1 | $4.62M | Buy |
278,508
+106,653
| +62% | +$2.02M | ﹤0.01% | 3111 |
|
|
2018
Q4 | $3.29M | Buy |
171,855
+167,210
| +3,600% | +$6.26M | ﹤0.01% | 3382 |
|
|
2018
Q3 | $243K | Buy |
+4,645
| New | +$253K | ﹤0.01% | 7925 |
|
|
2018
Q2 | – | Sell |
-8,324
| Closed | -$308K | – | 9395 |
|
|
2018
Q1 | $308K | Buy |
+8,324
| New | +$222K | ﹤0.01% | 6712 |
|
Citadel Advisors's GTHX Position: Q3 2024 in Review
Citadel Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 239 shares — an estimated $545 sold.
Citadel Advisors first reported a position in GTHX in Q1 2018 and held it in 25 quarters. The position peaked at $4.62M in Q1 2019. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Citadel Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Citadel Advisors sold 239 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $545.
- Citadel Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 25 quarters.
- Citadel Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $4.62M in Q1 2019.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.